Feigal Ellen 4

What Happened
Ellen Feigal, a director of NextCure, was granted a compensatory derivative award of 2,340 shares on June 18, 2026. The Form 4 reports the acquisition as 2,340 shares at $0.00 (derivative), so no cash was paid at grant. This was a grant/award (not a market purchase or sale).

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-22. Filing does not indicate a late filing.
• Reported transaction: Code A (award/grant) — 2,340 derivative shares acquired at $0.00.
• Shares owned after the transaction: Not disclosed in the provided filing.
• Footnote F1: "The option vests in full on the earlier of June 18, 2027 and the date of the 2027 Annual Meeting of Stockholders."
• Nature: Compensatory director award; not reported as a sale or open-market purchase.

Context
This is a routine director compensation grant that will vest by mid‑2027 per the footnote. Derivative awards typically convert to common shares (or give right to acquire shares) only after vesting and any exercise requirements are met, so this does not reflect an immediate market purchase or sale. As with most director grants, it is a compensation event rather than a direct market sentiment signal.